Millie Nelson

Life Sciences partnering events company EBD Group discusses the importance of communication, education, and the trials and tribulations of organizing an event with sustainability in mind.

ScaleReady and Germfree discuss the need to rethink sustainability and move towards a more standardized and simplistic manufacturing model to ensure health equity can be achieved.

An expert from Alltrna discusses how transfer RNA (tRNA) can be used to treat rare diseases.

Eli Lilly has proposed a $364 million investment in the UK to launch the first Lilly Gateway Labs innovation space in Europe. Meanwhile, similar plans are underway in Beijing, China with two labs planned to support startups.

Q&A: Vetter Pharma SVP says both environmental and social sustainability are essential for pharmaceutical, biotechnology, and biomanufacturing companies.

Panelists at EBD's BIO Europe debated whether culture is the main reason US average funding rounds are double that across the pond.

BioXconomy sat down with Natalie Kuldell, founder and executive director of nonprofit organization BioBuilder Education Foundation, to discuss its function, its importance, and its effect in the life sciences space.

Pharma is being more selective in the deals it strikes among what a panel of experts say is an abundance of players looking to partner.

Investors at LSX Investival discuss how, after securing Series A funding, biotech companies should begin to lay the groundwork for Series B financing.

Novo Nordisk's rapid growth marks its success, but firm veteran Tomas Landh said it comes at a cost, such as tension bred through acquisitions.